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Abstract
Background: Following the demonstration that histone deacetylase inhibitors enhanced experimental radiation-induced
clonogenic suppression, the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study, combining fractionated radiotherapy
with daily vorinostat for pelvic carcinoma, was designed to evaluate both clinical and novel biomarker endpoints, the latter
relating to pharmacodynamic indicators of vorinostat action in clinical radiotherapy.
Patients and Methods: Potential biomarkers of vorinostat radiosensitizing action, not simultaneously manifesting molecular
perturbations elicited by the radiation itself, were explored by gene expression array analysis of study patients’ peripheral
blood mononuclear cells (PBMC), sampled at baseline (T0) and on-treatment two and 24 hours (T2 and T24) after the
patients had received vorinostat.
Results: This strategy revealed 1,600 array probes that were common for the comparisons T2 versus T0 and T24 versus T2
across all of the patients, and furthermore, that no significantly differential expression was observed between the T0 and
T24 groups. Functional annotation analysis of the array data showed that a significant number of identified genes were
implicated in gene regulation, the cell cycle, and chromatin biology. Gene expression was validated both in patients’ PBMC
and in vorinostat-treated human carcinoma xenograft models, and transient repression of MYC was consistently observed.
Conclusion: Within the design of the PRAVO study, all of the identified genes showed rapid and transient induction or
repression and therefore, in principle, fulfilled the requirement of being pharmacodynamic biomarkers of vorinostat action
in fractionated radiotherapy, possibly underscoring the role of MYC in this therapeutic setting.
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Introduction
Modern radiation oncology will require a synergy between high-
precision radiotherapy protocols and innovative approaches for
biological optimization of radiation effect. From a clinical
perspective, new insights into molecular radiobiology will provide
a unique opportunity for combining systemic targeted therapeutics
with radiotherapy [1]. One example is the use of histone
deacetylase (HDAC) inhibitors as potentially radiosensitizing
drugs. Inhibition of HDAC enzymes leads to acetylation of
histone and non-histone proteins, and the resultant changes in
gene transcription cause alterations in key molecules that
orchestrate a wide range of cellular functions, including cell cycle
progression, DNA damage signaling and repair, and cell death by
apoptosis and autophagy [2–5].
Following the demonstration that HDAC inhibitors enhanced
radiation-induced clonogenic suppression of experimental in vitro
and in vivo colorectal carcinoma models [6–9], but independently
of the actual histone acetylation level at the time of radiation
exposure [7,8], we conducted the Pelvic Radiation and Vorinostat
(PRAVO) phase 1 study [10,11]. This trial, undertaken in
sequential patient cohorts exposed to escalating dose levels of
the HDAC inhibitor vorinostat combined with pelvic palliative
radiotherapy for advanced gastrointestinal malignancy, was the
first to report on the therapeutic use of an HDAC inhibitor in
clinical radiotherapy. It was designed to demonstrate a number of
key questions; whether the investigational agent reached the
specific target (detection of tumor histone acetylation), the
applicability of non-invasive tumor response assessment (using
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functional imaging), and importantly, that the combination of an
HDAC inhibitor and radiation was safe and tolerable.
The ultimate goal of a first-in-human therapy trial is to conclude
with a recommended treatment dose for follow-up expanded trials,
and in achieving this, a phase 1 study typically is designed to
determine treatment toxicity and tolerability (in terms of dose-
limiting toxicity and maximum-tolerated dose (MTD), respective-
ly) [12,13]. For molecularly targeted agents, the dose that results in
a relevant level of target modulation may differ greatly from the
MTD, and generally, we do not have a good understanding of the
relationship between the MTD and the dose required to achieve
the desired therapeutic effect [1]. An optimum biological dose may
be the dose that is associated with pharmacodynamic biomarkers
reflecting the mechanism of drug action. In the setting of
fractionated radiotherapy, this would ideally represent a radio-
sensitizing molecular event occurring at each radiation fraction, or
in other words, a biological indicator with a transient and periodic
expression profile. Importantly, tumor specimens for this partic-
ular purpose cannot be sampled after the patient has commenced
the radiation treatment. Any signaling activity in on-treatment
tumor samples would reflect the combined effect of radiation and
the systemic drug, and the contribution of the latter would
probably be indistinguishable from the effect of the actual
accumulated radiation dose. Instead, the study can be designed
to collect non-irradiated surrogate tissue both before the
commencement of study treatment and on-treatment at time
points reflecting the timing of administration of the systemic drug
with regard to the fractionated radiotherapy protocol. In addition,
as a general rule, biomarkers that have been previously established
for single-agent therapy will require reevaluation in a first-in-
human clinical trial combining a molecularly targeted compound
with radiotherapy.
Within this context, i.e., that the possible mechanism of
radiosensitizing action of the molecularly targeted agent should
be regarded a main objective in a combined-modality study with
radiotherapy, the present study reports on a correlative analytical
strategy for identifying possible biomarkers of HDAC inhibitor
activity, using peripheral blood mononuclear cells (PBMC) from
the PRAVO phase 1 study patients receiving pelvic palliative
radiotherapy as an easily accessible surrogate tissue for vorinostat
exposure [14]. Gene expression array analysis identified PBMC
genes that from experimental models are known to be implicated
in biological processes governed by HDAC inhibitors, and might
be further developed as pharmacodynamic biomarkers of vorino-
stat activity in the setting of fractionated radiotherapy.
Materials and Methods
Ethics Statement
Both of the protocols for the PRAVO study (ClinicalTrials ID
NCT00455351) and the phase 2, non-randomized study for
patients with locally advanced rectal cancer (LARC) given
neoadjuvant chemoradiotherapy (ClinicalTrials ID
NCT00278694) were approved by the Institutional Review Board
and the Regional Committee for Medical and Health Research
Ethics South-East Norway (REC South-East, Permit Number S-
06289 and S-05059, respectively), and were performed in
accordance with the Declaration of Helsinki. Written informed
consent was required for participation. Housing and all procedures
involving animals were performed according to protocols
approved by the Animal Care and Use Committee at Department
of Comparative Medicine, Oslo University Hospital (Permit
Number 885–2616–2919–2928–3688), in compliance with the
Norwegian National Committee for Animal Experiments’ guide-
lines on animal welfare.
PRAVO Study Patients and Objectives
The patient population was enrolled between February 2007
and May 2009. The principal eligibility criterion was histologically
confirmed pelvic carcinoma scheduled to receive palliative
radiation to 30 Gy in 3-Gy daily fractions. Other details on
eligibility are given in the initial report [10]. This phase 1 dose-
escalation study adopted a standard 3+3 expansion cohort design
[12], where patients with advanced gastrointestinal carcinoma
were enrolled onto four sequential dose levels of vorinostat (Merck
& Co., Inc., Whitehouse Station, NJ, USA), starting at 100 mg
daily with dose escalation in increments of 100 mg [10]. The
primary objective was to determine tolerability of vorinostat,
defined by dose-limiting toxicity and MTD, when administered
concomitantly with palliative radiation to pelvic target volumes.
Secondary objectives were to assess the biological activity of
vorinostat, including the identification of possible biomarkers of
HDAC inhibitor activity, and to monitor radiological response
when given with pelvic radiotherapy. The study data on patient
treatment tolerability, tumor histone acetylation following vorino-
stat administration, and treatment-induced changes in tumor
volume and apparent distribution coefficient, as assessed by
magnetic resonance imaging, have been reported in detail
previously [10,11].
Patient Blood Sampling and RNA Isolation
As depicted by Figure 1, peripheral blood, drawn on PAXgene
Blood RNA Tubes (Qiagen Norge, Oslo, Norway), was collected
at baseline (before commencement of study treatment; termed T0)
and on-treatment the third treatment day, two and 24 hours after
the patient had received the preceding daily dose of vorinostat
(termed T2 and T24), respectively. A full set of three samples (T0,
T2, and T24) was obtained from 14 of the 16 evaluable study
patients (Table 1). The tubes were stored at 270uC until analysis.
Total PBMC RNA was isolated using PAXgene Blood RNA Kit
(Qiagen), following the manufacturer’s protocol. RNA concentra-
tion and quality were assessed using NanoDrop 1000 and Agilent
2100 Bioanalyzer (Thermo Fisher Scientific Norway, Oslo,
Norway), respectively.
Gene Expression Array Analysis
This analysis was performed by the Norwegian Genomics
Consortium (Oslo, Norway). Briefly, cRNA synthesis, amplifica-
tion, and hybridization to Illumina Human WG-6 v3 Expression
BeadChip arrays (Illumina, Inc., San Diego, CA, USA), contain-
ing 48,000 probes, were carried out as per manufacturer’s
instructions. Signal intensities were extracted by the BeadArray
Reader Software (Illumina), and raw data were imported into the
GenomeStudio v2010.1 Software, Gene Expression module v1.6.0
(Illumina). The primary array data are available in the Gene
Expression Omnibus data repository (GEO accession number
GSE46703).
Statistical and Functional Annotation Analyses of Array
Data
Analysis was performed using Bioconductor vR2.11.1 and the
Bioconductor packages lumi 1.14.0, linear models for microarray
data (limma) 3.4.4, and illuminaHumanv3BeadID.db 1.6.0 (www.
bioconductor.org). Following quality control and pre-processing,
the data were log2-transformed, and differential gene expression
between the sample groups T0, T2, and T24 was determined by
HDAC Inhibitor Activity in Clinical Radiotherapy
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applying a Benjamin and Hochberg false discovery rate-adjusted
P-value cut-off of 0.05. The total number of probes that were
identified as differentially expressed was analyzed using the
Database for Annotation, Visualization and Integrated Discovery,
DAVID v6.7 [15,16]. Enriched biological processes and pathways
were identified using the GOTERM_BP_FAT and KEGG_-
PATHWAY algorithms, applying a P-value cut-off of 0.01.
Differential expression analysis of the array data was also
performed using a P-value of 0.01 and a log2-fold change cut-off
of 1.0 in order to identify genes whose expression changes could
have potentially high biological significance.
Experimental Human Colorectal Carcinoma Models
The HCT116 and SW620 colorectal carcinoma cell lines were
originally purchased from American Type Culture Collection
(Manassas, VA, USA), and the identities of our laboratory’s
versions were confirmed by short tandem repeat analysis (Table
S1). The LoVo-92 colorectal carcinoma cell line was kindly
provided by Dr. Paul Noordhuis (VU Medical Centre, Amster-
dam, The Netherlands) [17]. The cell lines were cultured as
previously described [8,17]. Xenografts were established by
subcutaneous injections of HCT116 or SW620 cell suspensions
(26106 cells) bilaterally on the flanks of locally bred female BALB/
c nude (nu/nu) or Athymic Nude-Foxn1nu mice, 6–8 weeks of age.
Vorinostat (Cayman Chemical, Ann Arbor, MI, USA; 100 mg/
kg, dissolved in dimethyl sulfoxide to a concentration of 100 mg/
ml immediately before use) or vehicle was given by intraperitoneal
injection 13 days (HCT116) or 20 days (SW620) after establish-
ment of xenografts. Three and 12 hours after administration, the
tumors were extirpated, snap-frozen in liquid nitrogen, and stored
at 270uC. The xenografts were sectioned using a cryostat
microtome prior to RNA extraction using TRIzolH Reagent
(Invitrogen Dynal AS, Oslo, Norway). RNA concentration was
assessed using the RNA/DNA calculator Gene Quent II
(Pharmacia Biotech, Piscataway, NJ, USA).
Tumor Samples from LARC Patients
Primary tumor biopsies were sampled at the time of diagnosis
from LARC patients enrolled onto a phase 2 study on neoadjuvant
chemoradiotherapy (Table S2). The biopsy samples were snap-
frozen in liquid nitrogen and stored at 270uC, and sectioned on
the cryostat microtome, essentially as previously reported [18],
before RNA was extracted.
Figure 1. Treatment schedule for the Pelvic Radiation and Vorinostat phase 1 study. This study combined pelvic palliative radiotherapy
(30 Gy in 3-Gy daily fractions; administered at 12 noon) with the histone deacetylase inhibitor vorinostat (given once daily at 9 a.m.) for advanced
gastrointestinal malignancy. Arrows indicate administration of therapy. Study patients’ peripheral blood mononuclear cells (PBMC) were sampled
before commencement of treatment (T0) and on active therapy, two hours (T2; at 11 a.m. on day 3) and 24 hours (T24; at 9 a.m. on day 3) after the
previous dose of vorinostat.
doi:10.1371/journal.pone.0089750.g001
Table 1. Study patients.
Vorinostat dose
(mg daily)
Age
(years) Gender Comment
100 77 female
200 49 female
200 64 female
200 66 female
300 47 female PBMC a not available
300 66 female
300 77 male
300 81 female
300 82 male
300 87 female PBMC a not available
400 45 female
400 55 male
400 62 male
400 75 female
400 83 female
400 85 female
aPeripheral blood mononuclear cells.
doi:10.1371/journal.pone.0089750.t001
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Reverse Transcriptase Quantitative Polymerase Chain
Reaction (RT-qPCR) Analysis
cDNA was synthesized from total RNA using the qScriptTM
cDNA Synthesis Kit (Quanta BioSciences, Inc., Gaithersburg,
MD, USA). The qPCR was run in Perfecta qPCR Supermix
(Quanta), on iCycler (Bio-Rad Laboratories Norway, Oslo,
Norway) and with all reactions in parallel. Primers were designed
using ProbeFinder Assay Design Software (www.roche-applied-
science.com/sis/rtpcr/upl/ezhome.html), and were obtained from
the Universal ProbeLibrary collection (Roche Applied Sciences,
Oslo, Norway). Primer sequences are listed in Table S3. Amplified
cDNA generated from the reference cell line (LoVo-92) was
included on all PCR plates for relative quantification purposes
(correction of plate-to-plate variation). Data were normalized to
the expression levels of two reference genes; YARS, encoding
tyrosyl-tRNA synthetase, and TBP, encoding the TATA box-
binding protein. When tested in the patient samples, the reference
genes had equal expression per ng of cDNA, independent of
patient treatment (vorinostat dose and time after administration).
The data were analyzed using the GeneExpression Analysis for
iCycler iQH Real-Time PCR Detection System Software
(BioRad), and were calculated relative to the level in the reference
cell line and subsequently log2-transformed.
Statistical Analysis of qPCR Data
Analysis was performed using Predictive Analytics SoftWare
Statistics version 19.0 (SPSS Inc., Chicago, IL, USA). Q-Q plots
were applied to test whether the data were normally distributed or
not, before differences between groups were analyzed using two-
sided Student t-test for the PBMC samples and Mann-Whitney U
test for xenograft samples. P-values less than 0.05 were considered
statistically significant.
Results
PBMC Transcriptional Response to Vorinostat – Biological
Processes and Pathways
Table 1 gives study patient baseline characteristics; the full study
data on treatment tolerability and response have been reported
previously [10,11]. Of the 14 patients that provided a full set of
PBMC samples (T0, T2, and T24), one patient was treated at
vorinostat 100 mg once daily and three patients at the 200 mg
dose level, whereas four and six patients received the medication at
300 or 400 mg once daily, respectively. Importantly, as vorinostat-
induced tumor histone acetylation had been observed at all dose
levels [10], the array data from all patient samples at each time
point (T0, T2, and T24) were pooled, irrespective of the vorinostat
dose administered to the patients. This was done to increase the
statistical power of the testing on analysis of differential gene
expression between the individual time points. As shown by
Figure 2, approximately 2,100 probes were differentially expressed
both at two hours of vorinostat exposure (T2 versus T0) and on the
T24 versus T2 comparison when applying the P-value cut-off of
0.05. Of these, 1,602 transcripts were found to be altered in both
comparisons, and furthermore, no significantly differential expres-
sion was observed when comparing the T0 and T24 groups.
Hence, all of the 1,602 mutual probes that were identified had a
transient change in expression level from T0, with approximately
one half found to be up-regulated and thus, the other half down-
regulated at T2, followed by the opposite directional change to
baseline expression at T24 (data not shown).
Functional annotation analysis of the differentially expressed
genes in patients’ PBMC identified several enriched biological
processes. Comparison of the baseline PBMC transcription profile
with that obtained two hours after vorinostat administration (T2
versus T0) showed that 69 biological processes were over-
represented, whereas the corresponding comparison of T24 versus
T2 transcriptional profiles identified 106 processes (Table S4). As
seen from Table 2, displaying the top-ten Gene Ontology terms for
each of the two comparisons, seven out of the ten biological
processes were present in both, with transcription being the most
significant. In addition, the analysis identified enrichment of genes
involved in catabolic processes, the cell cycle, RNA processing,
chromatin modification, and chromosome organization. The top-
three pathway networks for each of the two comparisons, in
common for both, comprised signaling factors of the cell cycle,
including the p53 pathway (Table 3).
Vorinostat Activity in PBMC – Verification of Selected
Biomarkers
Next, by introducing a log2-fold change cut-off of 1.0 while
decreasing the P-value to 0.01 in order to identify gene expression
changes with presumably high biological significance, the list of
differentially expressed probes, all with a biphasic pattern of
regulation from T0 through T2 and T24, was reduced to 38
candidates (Table 4). Within this panel, two genes had duplicate
array probes, whereas no reference sequence could be identified
for three other probes, leaving 33 known genes as transcriptionally
regulated by vorinostat following this stringent statistical analysis of
the array data.
Selection of genes for verification analysis by RT-qPCR was
based on both the relevance in the DNA damage response, which
is recognized as a significant mechanism contributing to clinical
radiation sensitivity [19], and previous indication of regulation by
HDAC inhibitors. Five of the 33 genes were found to fulfill both
criteria: MYC [20,21] among the ten genes repressed at T2 and
Figure 2. Venn diagram illustrating differentially expressed
genes. Study patients’ peripheral blood mononuclear cells were
sampled at baseline (T0) and on-treatment two and 24 hours after
administration of the daily dose of the study medication vorinostat (T2
and T24, respectively). Gene expression was analyzed by Illumina
Human WG-6 v3 Expression BeadChip arrays. The array data from all
patient samples at each time point (T0, T2, and T24) were pooled for the
analysis. Probes with false discovery rate-adjusted P-values less than
0.05 were considered differentially expressed and subjected to Venn
analysis, comparing by pairs T2 versus T0, T24 versus T2, and T24 versus
T0. The figures represent numbers of probes in common for the various
conditions.
doi:10.1371/journal.pone.0089750.g002
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correspondingly, GADD45B [22], MSH6 [23,24], BARD1 [25,26],
and DDIT3 [27,28] among the 23 induced genes; mean PBMC
expression levels at T0 relative to reference cell line expression are
given in Table S5. These genes were present within the enriched
biological processes and pathways identified by the functional
annotation analysis of the differentially expressed genes (Table 2
and Table 3), and the biphasic pattern of regulation in PBMC
through T2 and T24 was confirmed with significant time-
dependent changes (P,0.01) for all of the five genes (Figure 3).
Vorinostat Activity in Experimental Tumors – Validation
of Selected Biomarkers
We have previously shown histone hyperacetylation in vorino-
stat-treated human colorectal carcinoma xenograft models
(HCT116 and SW620), peaking three hours after vorinostat
administration and with restored baseline levels of histone
acetylation three to six hours later, without accumulative effect
following repeat daily administration [8]. Hence, expression of the
five selected genes was further assessed by RT-qPCR in HCT116
and SW620 xenografts, three and 12 hours after administering
vorinostat to tumor-bearing mice; median control expression levels
relative to reference cell line expression are given in Table S5. In
the HCT116 model, a significant change (P,0.05) in vorinostat-
induced expression was found for MYC only. A similar transient
MYC repression, but without statistically significant differences in
expression levels through the time points, was seen in the SW620
tumors (Figure 3).
Table 2. Enriched biological processes in patients’ peripheral blood mononuclear cells during 24 hours of vorinostat treatment.
Biological process a n (%) P-value Selected transcripts b
T2 versus T0 c
GO:0006350 transcription 253 (17) 5.1610214 MYC, DDIT3
GO:0044265 cellular macromolecule catabolic process 107 (7.2) 8.2610211 MYC, BARD1
GO:0044257 cellular protein catabolic process 93 (6.3) 1.7610210 BARD1
GO:0007049 cell cycle 111 (7.5) 2.3610210 MYC, MSH6, BARD1, DDIT3
GO:0051603 proteolysis involved in cellular protein catabolic process 92 (6.2) 2.9610210 BARD1
GO:0019941 modification-dependent protein catabolic process 89 (6.0) 3.4610210 BARD1
GO:0009057 macromolecule catabolic process 111 (7.5) 3.4610210 MYC, BARD1
GO:0030163 protein catabolic process 94 (6.6) 3.9610210 BARD1
GO:0006396 RNA processing 84 (5.6) 1.861029
GO:0045449 regulation of transcription 276 (19) 5.061029 MYC, DDIT3
T24 versus T2 c
GO:0006350 transcription 260 (17) 8.3610216 MYC, DDIT3
GO:0007049 cell cycle 114 (7.5) 2.6610211 MYC, MSH6, BARD1, DDIT3
GO:0045449 regulation of transcription 286 (19) 5.4610211 MYC, DDIT3
GO:0016568 chromatin modification 55 (3.6) 1.3610210
GO:0006396 RNA processing 86 (5.6) 3.7610210
GO:0044265 cellular macromolecule catabolic process 104 (6.8) 8.8610210 MYC, BARD1
GO:0051276 chromosome organization 78 (5.1) 9.6610210 MSH6
GO:0022402 cell cycle process 85 (5.6) 4.161029 MYC, MSH6, BARD1, DDIT3
GO:0044257 cellular protein catabolic process 89 (5.8) 4.361029 BARD1
GO:0009057 macromolecule catabolic process 107 (7.0) 6.461029 MYC, BARD1
aGene Ontology (GO) terms in bold: present in both comparisons.
bVerified by reverse transcriptase quantitative polymerase chain reaction analysis.
cT0 represents baseline peripheral blood mononuclear cells (PBMC) samples; T2 and T24 represent PBMC samples collected two and 24 hours, respectively, after the
patients had received the daily dose of vorinostat.
doi:10.1371/journal.pone.0089750.t002
Table 3. Enriched biological pathways in patients’ peripheral blood mononuclear cells during 24 hours of vorinostat treatment.
Biological pathway n (%) P-value Genes a
hsa04130 SNARE interactions in vesicular transport 10 (0.85) 1.661024 STX6, STX5, STX1A, STX12, STX16, USE1, BET1, BET1L, GOSR1, VAMP1
hsa04115 p53 signaling pathway 13 (1.1) 2.761024 PMAIP1, RRM2B, SESN2, CDK4, CDK2, CCNE2, CCNE1, PPM1D, TNFRSF10B,
RCHY1, APAF1, GADD45B, GADD45A
hsa04110 cell cycle 17 (1.5) 0.0012 CCNH, ANAPC13, CDC23, CDK7, PTTG1, CDK4, ZBTB17, TGFB1, WEE1, CDK2,
CCNE2, CCNE1, YWHAG, CDKN2D, GADD45B, GADD45A, MYC
aGenes in bold: verified by reverse transcriptase quantitative polymerase chain reaction analysis.
doi:10.1371/journal.pone.0089750.t003
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Table 4. Differentially expressed genes in patients’ peripheral blood mononuclear cells during 24 hours of vorinostat treatment. a
Accession no. Gene b Gene name
T2 versus T0 c (log2-fold
change)
T24 versus T2 c (log2-fold
change)
NM_005627 SGK1 serum/glucocorticoid regulated kinase 1 21.58 1.65
NM_016478 ZC3HC1 zinc finger, C3HC-type containing 1 21.43 1.39
NM_175571 GIMAP8 GTPase, IMAP family member 8 21.23 1.34
NM_206938 MS4A7 membrane-spanning 4-domains, subfamily A,
member 7
21.21 1.06
NM_002467 MYC v-myc myelocytomatosis viral oncogene
homolog (avian)
21.20 1.09
NM_001024938 SLC2A11 solute carrier family 2 (facilitated glucose
transporter), member 11
21.16 1.17
NM_004843 IL27RA interleukin 27 receptor, alpha 21.14 1.05
NM_000104 CYP1B1 cytochrome P450, family 1, subfamily B,
polypeptide 1
21.13 1.26
NM_207007 CCL4L2 chemokine (C-C motif) ligand 4-like 2 21.04 1.26
NM_014167 CCDC59 coiled-coil domain containing 59 21.02 1.00
NM_005346 HSPA1B heat shock 70kDa protein 1B 1.82 22.02
NM_153812 PHF13 PHD finger protein 13 1.80 21.95
NM_001564 ING2 inhibitor of growth family, member 2 1.59 21.71
NM_001564 ING2 inhibitor of growth family, member 2 1.56 21.56
NM_001001870 none none 1.42 21.28
NM_016639 TNFRSF12A tumor necrosis factor receptor superfamily,
member 12A
1.40 21.33
NM_152339 SPATA2L spermatogenesis associated 2-like 1.38 21.46
NM_025079 ZC3H12A zinc finger CCCH-type containing 12A 1.36 21.29
NM_015675 GADD45B growth arrest and DNA-damage-inducible, beta 1.30 21.17
NM_013368 SERTAD3 SERTA domain containing 3 1.24 21.30
NM_004219 PTTG1 pituitary tumor-transforming 1 1.23 21.35
NM_014711 CP110 CP110 protein 1.20 21.21
NM_005341 ZBTB48 zinc finger and BTB domain containing 48 1.14 21.03
NM_000179 MSH6 mutS homolog 6 (E. coli) 1.13 21.23
NM_153358 ZNF791 zinc finger protein 791 1.13 21.07
NM_006494 ERF Ets2 repressor factor 1.12 21.06
NR_002734 PTTG3P pituitary tumor-transforming 3, pseudogene 1.11 21.18
NM_016605 FAM53C family with sequence similarity 53, member C 1.07 21.13
NM_004219 PTTG1 pituitary tumor-transforming 1 1.07 21.13
not available none transcribed locus Hs.559604 1.07 21.08
NM_000024 ADRB2 adrenergic, beta-2-, receptor, surface 1.07 21.07
XM_926814 none none 1.05 21.19
NM_006806 BTG3 BTG family, member 3 1.05 21.04
NM_031212 SLC25A28 solute carrier family 25 (mitochondrial iron
transporter), member 28
1.05 21.00
NM_000465 BARD1 BRCA1 associated RING domain 1 1.02 21.23
NM_004083 DDIT3 DNA-damage-inducible transcript 3 1.02 21.08
NM_052901 SLC25A25 solute carrier family 25 (mitochondrial carrier;
phosphate carrier), member 25
1.02 21.06
NM_024954 UBTD1 ubiquitin domain containing 1 1.01 21.01
aLog2-fold change higher than 1.0; P-value less than 0.01.
bGenes in bold: chosen for validation of expression in the study patients’ peripheral blood mononuclear cells (PBMC) samples and human colorectal carcinoma
xenograft models.
cT0 represents baseline PBMC samples; T2 and T24 represent PBMC samples collected two and 24 hours, respectively, after the patients had received the daily dose of
vorinostat.
doi:10.1371/journal.pone.0089750.t004
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LARC – Primary Tumor MYC Expression
On identifying MYC repression as a possible biomarker of
HDAC inhibitor activity from the strategy of analyzing, firstly,
PRAVO study patients’ PBMC, and secondly, vorinostat-treated
colorectal carcinoma xenografts, and additionally recognizing this
drug as a rational approach for biological optimization of radiation
effect in pelvic gastrointestinal carcinoma [10], we investigated
whether MYC might be expressed in the target tissue of a well-
established pelvic radiotherapy protocol. In 27 LARC patients
receiving neoadjuvant chemoradiotherapy [18], MYC expression
was detected in all primary tumor samples, though at highly
variable levels (median expression value was 0.47 (range 0.020–
4.9) relative to reference cell line expression), but was essentially
not associated with patient characteristics or treatment outcome in
this small cohort (Table S2).
Discussion
Within the design of the PRAVO phase 1 study (Figure 1),
combining the HDAC inhibitor vorinostat with fractionated
radiation to pelvic targets volumes for determination of treatment
tolerability and response, gene expression array analysis was
performed of study patients’ PBMC, sampled at baseline (T0) and
on-treatment two and 24 hours (T2 and T24) after the patient had
received the daily dose of vorinostat, in order to identify possible
biomarkers of HDAC inhibitor activity. This strategy revealed
1,600 array probes with biphasic pattern of expression from T0
through T2 and T24 across all of the study patients. A significant
number of these genes were found implicated in processes
comprising gene regulation, the cell cycle, and chromatin biology.
Applying stringent criteria for array data analysis, five genes were
recognized both as players in the DNA damage response and
targets for regulation by HDAC inhibitors, and were therefore
selected for validation of expression pattern both in study patients’
PBMC and in human colorectal carcinoma xenograft models. Of
these, only MYC consistently showed rapid and transient
repression in all conditions that were tested.
In the setting of fractionated radiotherapy, a synergistic drug
should preferably elicit a radiosensitizing molecular event at each
radiation fraction; hence, a pharmacodynamic biomarker should
reflect the timing of drug administration with regard to radiation
exposure in a periodic manner [1]. Importantly, in a prior
preclinical in vivo study combining vorinostat and fractionated
radiation, we observed that tumor histone acetylation, considered
a biomarker of vorinostat activity in the radiotherapy target tissue,
reached a maximum three hours after intraperitoneal vorinostat
injection into the experimental animals and was restored to
baseline acetylation level three to six hours later, but with a
repetitive, transient induction of acetylation following repeat
injections. Of note, tumor growth inhibition after fractionated
radiation, representing a long-term phenotypic outcome of the
experimental manipulations, was significantly enhanced both
when radiation was delivered at peak and restored histone
acetylation levels [8]. Consequently, tumor histone hyperacetyla-
tion did not seem to be required at the time of radiation exposure,
leaving the question of the optimum temporal relationship
between administration of the radiosensitizing drug and radiation
delivery unaddressed.
In the PRAVO study, one patient at each vorinostat dose level
had both baseline (before commencement of study treatment)
and repeat tumor biopsy two-and-a-half hours after administra-
tion of vorinostat (on day 3 of the treatment protocol). Histone
hyperacetylation was observed in all on-treatment biopsy samples
[10], confirming the presence of vorinostat in the target at the
time of the daily radiation exposure. However, given that one of
the objectives of the study was to determine mechanisms of the
presumed radiosensitizing action of vorinostat that were not
simultaneously manifesting molecular perturbations elicited by
the radiation itself, non-irradiated surrogate tissue was collected
for the purpose of identifying new biomarkers. Several investi-
gators have demonstrated PBMC histone hyperacetylation on
HDAC inhibitor treatment [14,29,30]. With these aspects in
mind, PBMC were deemed to represent a relevant surrogate
tissue for studying radiosensitizing effects of vorinostat in the
context of this clinical trial.
Interestingly, using the study patients’ PBMC as surrogate tissue
for vorinostat exposure, all of the 1,600 probes that were found to be
common for the comparisons T2 versus T0 and T24 versus T2 in
principle represented pharmacodynamic biomarkers of the chosen
timing of vorinostat administration in the fractionated radiotherapy
Figure 3. Validation of vorinostat-regulated expression of
selected genes. Study patients’ peripheral blood mononuclear cells
(PBMC) were sampled at baseline (T0) and on-treatment two (T2) and 24
(T24) hours after administration of the daily dose of the study
medication vorinostat, and expression of MYC, GADD45B, MSH6, BARD1,
and DDIT3 was analyzed by reverse transcriptase quantitative polymer-
ase chain reaction (RT-qPCR). Correspondingly, mice bearing HCT116 or
SW620 xenografts were injected intraperitoneally with vehicle (control,
C) or vorinostat, and xenografts were harvested three (T3) and 12 (T12)
hours after injection for RT-qPCR analysis of MYC expression. Relative
gene expression (log2-fold change) for each comparison is given as
mean 6 SEM of the PBMC sample values (n=14) and as median and
range of the values from control (n= 8 for HCT116; n= 4 for SW620) and
vorinostat-treated (n=4 for HCT116; n=2 for SW620) xenografts. The
compared gene expression levels were significantly different within the
PBMC (P,0.01) and HCT116 (P,0.05) sample groups, while the
differences were non-significant for the SW620 tumors.
doi:10.1371/journal.pone.0089750.g003
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protocol. The genes showed rapid and transient induction or
repression, thus mirroring the kinetics of the histone acetylation
response. This observation implies that the design of the PRAVO
study, undertaken in patients with advanced gastrointestinal cancer,
may not have provided the optimum context for detailed capture of
molecular effects of vorinostat. Thus, ethical concerns may
challenge the structure required within a clinical trial setting for
evaluating novel biomarker endpoints. Nevertheless, in the PRAVO
study, functional annotation analysis of the panel of 1,600 probes
identified biological processes and pathways comprising gene
regulation (transcription, RNA processing), cell cycle progression
(including p53 signaling, commonly involved in the DNA damage
response), and chromatin biology. These findings are consistent with
well-known cellular perturbations following exposure of experi-
mental tumor models to HDAC inhibitors [2–5].
Investigation of biomarkers of HDAC inhibitor activity has
been undertaken in a number of clinical therapy trials. These
include the demonstration of increased histone acetylation in
patients’ PBMC in the early trials [14,29,30] and the more recent
confirmation of changes in tumor expression of acetylated histone
and non-histone proteins [10,14,31,32], the HDAC2 enzyme [31]
and HR23B protein [33,34], the latter been proposed as predictive
biomarker [35], and of tumor proliferation index [36]. Plasma
protein profiling has been done in glioblastoma patients receiving
vorinostat in combination with an established cytotoxic regimen
[37]. Furthermore, tumor gene expression array analysis has been
performed in a study with the HDAC inhibitor panobinostat as
single agent [38] and in one trial each of combining either
vorinostat or valproate with other biologic agents (in non-small cell
lung carcinoma and acute myeloid leukemia, respectively) [39,40].
To our knowledge, the present study is the first to report on gene
expression array analysis as an attempt to identify pharmacody-
namic biomarker(s) reflecting timing of HDAC inhibitor admin-
istration with regard to an established cytotoxic regimen.
The criteria for selecting genes for validation were both their
presumed relevance in the DNA damage response and previous
indications of regulation by an HDAC inhibitor [22–24,28,41],
and additionally, in order to find ‘tumor-specific’ markers,
omitting genes that typically might be associated with leukocyte
biology. Four of the selected genes were induced by vorinostat in
the study patients’ PBMC but did not show a similar response in
the experimental tumor models. BARD1 encodes a nuclear factor
with tumor suppressor activity [24], the stress response effectors
encoded by GADD45B and DDIT3 are implicated in cell cycle
arrest, DNA repair, and apoptosis [42,43], and MSH6 encodes a
DNA mismatch repair protein [44]. To date, only three studies
seem to have been published on their potential use as biomarkers
of therapy response [45–47]. In contrast, the confirmation of MYC
as the only one of the selected genes with rapid and transient
change in expression in all tested conditions (i.e., both in the study
patients’ PBMC and experimental tumor models) may point to a
particular importance of myc in the therapeutic setting with
fractionated radiation. Future investigations of vorinostat as
possible radiosensitizing agent might be within a long-term
curative radiotherapy protocol, for example as an additional
component of neoadjuvant chemoradiotherapy for LARC. The
confirmed presence of MYC expression in the intended radiother-
apy target tissue (primary rectal tumors) in LARC patients
encourages future exploration of this proto-oncogene as a novel
biomarker endpoint.
The myc protein acts both as transcriptional activator and
repressor, regulating a myriad of genes that collectively conduct
cell cycle progression, apoptosis, angiogenesis, and genetic
instability [48]. Specifically, it has been suggested that myc
activates DNA damage repair genes [20], and interestingly, that
myc in hypoxic tumors acts synergistically with the transcription
factor hypoxia-inducible factor type 1a, HIF-1a [49,50]. Recent
evidence indicates that HDAC inhibition suppresses HIF-1a
activity [51,52]. Consequently, mitigation of DNA damage repair
capacity through suppression of myc/HIF-1a synergy in hypoxic
tumors [53,54], typically being resistant to radiation, provides an
appealing explanation for the radiosensitizing effect of HDAC
inhibitors.
However, conflicting data have been presented as to how
HDAC inhibition may influence the myc protein itself. Whereas
inhibition of various HDAC enzymes has been shown to cause
myc repression in a range of human cancer cell lines [21,55–57],
which corresponds well with the data in the present study, specific
nuclear induction of myc to mediate HDAC inhibitor-induced
apoptosis in glioblastoma cell lines has also been demonstrated
[58]. Interestingly, in nasopharyngeal carcinoma cells that were
resistant to radiation, myc was found to be essential through the
transcriptional activation of cell cycle checkpoint kinases [59],
which are signaling factors implicated in DNA damage repair,
thereby facilitating tumor cell survival following radiation expo-
sure. On the contrary, although radiosensitization was conferred
by HDAC inhibition both in hypoxic and normoxic hepatocellular
carcinoma cells, a lower level of myc expression was associated
with the hypoxic and more radioresistant condition [60]. Of
particular note, in the present study, the vorinostat-induced
repression of MYC was found both in study patients’ PBMC,
clearly representing normoxic tissue, and experimental tumors
that also were tested under normoxic conditions.
In conclusion, integral in the PRAVO study design was the
collection of non-irradiated surrogate tissue for the identification of
biomarker(s) of vorinostat activity to reflect the timing of
administration and also suggest the mechanism of action of the
HDAC inhibitor. This objective was achieved by gene expression
array analysis of study patients’ PBMC and as a consequence, the
identification of genes that from experimental models are known
to be implicated in biological processes and pathways governed by
HDAC inhibitors. Importantly, all of the identified genes showed
rapid and transient induction or repression and therefore, in
principle, fulfilled the requirement of being pharmacodynamic
biomarkers for this radiosensitizing drug in fractionated radio-
therapy. Among the identified candidate genes, MYC repression
was found in all patient samples and tested experimental
conditions, possibly underscoring the impact of the myc proto-
oncogene in this particular therapeutic setting.
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